Robert Hariri
Company: Celularity
Job title: CEO
Seminars:
Preclinical and Clinical Development of Human Placental Hematopoietic Stem Cell Derived NK Cells (CYNK001) for the Treatment of COVID-19 4:20 pm
day: Day Two
Preclinical and Clinical Development of Human Placental Hematopoietic Stem Cell Derived NK Cells (CYNK001) for the Treatment of COVID-19 4:20 pm
• Celularity has developed a novel proprietary GMP procedure that enables the scalable production of an off-the-shelf, allogeneic NK cell therapy (CYNK-001) • Combining pathogenic mechanism of coronavirus, existing and validated research results, we hypothesize adoptive CYNK001 therapy may provide the antiviral activities thereby serve as effective solutions for COVID-19 patients • Discuss the initial…Read more
day: Day Two